Karo Pharma is poised to expand its skin-care offering and establish a presence in Europe’s dietary supplements market with the acquisition of Belgium’s Sylphar Group from founder Robin List and Vendis Capital for €290m ($325m).
Described by Karo as a “fast-growing and digital-first” consumer health company, Sylphar develops and sells OTC products in 50 countries around the world, with its major
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?